Healthcare / Medical DevicesHKSE
$9.43
+0.18 (+1.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $345.7M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.6B
P/E
11.5x
↓EV/EBITDA
7.0x
↓ROE
9.1%
↑Gross Margin
66.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.5%
FCF CAGR
+177.9%
FCF margin
33.1%
FCF / Net income
1.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.05B · net income $272.5M · FCF $345.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.05B | $1.05B | $805.9M | $1.21B | $1.20B |
| Net Income | $272.5M | $272.5M | $125.0M | $277.8M | $307.7M |
| EBITDA | $312.3M | $312.3M | $141.0M | $315.5M | $345.7M |
| EPS | — | — | 0.33 | 0.72 | 0.80 |
| Gross Margin | 66.0% | 66.0% | 66.6% | 72.5% | 76.0% |
| Operating Margin | 30.9% | 30.9% | 16.4% | 24.2% | 27.7% |
| Net Margin | 26.1% | 26.1% | 15.5% | 23.0% | 25.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.09 | 6.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $345.7M | $345.7M | $-51.1M | $478.5M | $16.1M |
| Returns | |||||
| ROE | 9.1% | 9.1% | 4.4% | 9.7% | 11.3% |
| Valuation | |||||
| P/E | 11.50 | 11.50 | 25.12 | 15.89 | 19.47 |
| EV/EBITDA | 7.04 | 7.04 | 14.48 | 9.90 | 14.57 |
| P/B | 1.21 | 1.21 | 1.13 | 1.52 | 2.20 |
| Growth & Yield | |||||
| Revenue Growth | 29.8% | 29.8% | -33.3% | 0.6% | — |
| EPS Growth | — | — | -54.2% | -10.0% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.33 → n/d
Residual
-8.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.